ERBB2 and breast carcinoma: Consistent with this, findings from Finn et al. also indicated that the non-luminal subtypes of HER2-positive breast cancer are more resistant to the beneficial effects of the CDK4/6 inhibitor palbociclib [229]; however, this drug has been associated with various dermatological toxicities such as alopecia (reviewed in [230]).